Respiratory disorders
17 results
Applied filters
The licence and supporting evidence for omalizumab biosimilar
21 January 2026One omalizumab biosimilar is currently available: Omlyco. Learn about the licensed indications, available preparations, supporting evidence and key differences.
Preparing to use omalizumab biosimilar
20 January 2026One omalizumab biosimilar (Omlyclo) is available and other biosimilars are in development. We offer general information and implementation advice.
SMRs in problematic polypharmacy: respiratory focus
13 January 2026Consultant pharmacists will use a case study to illustrate a patient centred approach to SMRs for patients with respiratory conditions.
Doxycycline for sinusitis
27 January 2025SPS PGD template for the supply of doxycycline for sinusitis in penicillin allergy and where an intranasal steroid is unsuitable or ineffective.
Fluticasone furoate nasal spray for sinusitis
27 January 2025SPS PGD template for the supply of fluticasone furoate nasal spray for sinusitis.
Clarithromycin for sore throat
27 January 2025SPS PGD template for the supply of clarithromycin for sore throat in those with a penicillin allergy.
Clarithromycin for otitis media
27 January 2025SPS PGD template for the supply of clarithromycin for otitis media in those with a penicillin allergy.
Mometasone furoate monohydrate nasal spray for sinusitis
27 January 2025SPS PGD template for the supply of mometasone furorate monohydrate nasal spray for sinusitis.
Penicillin V (phenoxymethylpenicillin) for sinusitis
27 January 2025SPS PGD template for the supply of penicillin V (phenoxymethylpenicillin) where an intranasal steroid is unsuitable or ineffective.
Penicillin V (phenoxymethylpenicillin) for sore throat
27 January 2025SPS PGD template for the supply of penicillin V (phenoxymethylpenicillin) for sore throat.